← Back to Clinical Trials
Recruiting Phase 4 NCT04102566

NCT04102566 Optimizing Pain Control in Transurethral Resection of the Prostate

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04102566
Status Recruiting
Phase Phase 4
Sponsor Benaroya Research Institute
Condition Pain
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2017-12-08
Primary Completion 2019-10-01

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Ibuprofen 600 mgEducation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 50 participants in total. It began in 2017-12-08 with a primary completion date of 2019-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to develop a multi-modal protocol for pain management after TURP that minimizes opioid use. The investigators hypothesize this approach will provide non-inferior pain control to the current standard of care which includes opioids as the primary agent. The investigators believe this is an important step in reducing the opioid epidemic in surgical patients.

Eligibility Criteria

Inclusion Criteria: * Are identified as candidates for TURP * Are 18 years of age or greater * Are proficient in English Exclusion Criteria: * Have filled an opioid prescription in the last 2 months * Have an allergy to a medication included in the protocol * Have a history of pelvic radiation * Have renal failure (Serum Cr \> 2.0 mg/dl), peptic ulcer disease, history of gastric bypass, cirrhosis, or other contraindication precluding use of NSAID's * Have liver failure, hepatitis, or alcohol abuse which precludes use of acetaminophen

Contact & Investigator

Central Contact

Ryan Donahue, MD

✉ ryan.donahue@vmmc.org

📞 2062236600

Frequently Asked Questions

Who can join the NCT04102566 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT04102566 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT04102566 currently recruiting?

Yes, NCT04102566 is actively recruiting participants. Contact the research team at ryan.donahue@vmmc.org for enrollment information.

Where is the NCT04102566 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT04102566 clinical trial?

NCT04102566 is sponsored by Benaroya Research Institute. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology